Breast Cancer Drugs Market Size, Competitive Landscape and Market Forecast - 2029

SKU: DMPH916 | Last Updated On: Jun 24 2022 | Available Formats

> Global Breast Cancer Drugs Market Expected to reach a high CAGR By 2029: DataM Intelligence

Global Breast Cancer Drugs Market is Segmented By Cancer Type (Hormone Receptors, HER2+, Hormone Receptors), By Therapy(Targeted Therapy, Chemotherapy, Immunotherapy,  Hormonal Therapy), By End-user(Hospitals, Cancer Centers, Clinics, Ambulatory Surgical Centers,  Others), By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029.

 

Market Overview

The Global "Breast Cancer Drugs Market" is expected to reach at a high CAGR  during the forecast period (2022-2029).  

Breast cancer is a condition when cancerous cells overpower the cells in the female breasts. It is a heterogeneous malignancy that is classified into different subtypes based on the status of the estrogen receptor (ER) and progesterone receptor (PR) — collectively known as hormone receptors (HRs) — and the human epidermal growth factor receptor 2 (HER2, also known as ERBB2). HR and HER2 status determine drug treatment options. Mammograms can detect breast cancer early, possibly before it has spread.

Market Dynamics

The breast cancer drugs market growth is driven by the rising prevalence of breast cancer coupled with the emergence of novel therapies, improving healthcare infrastructure across emerging economies, and rising health awareness among patients are some driving factors for the market growth. Early detection of cancer also helps in increasing the survival rate, better life quality, and improved treatment options. Moreover, increased intensive research and development in the field of cancer, technological advancements, and an increase in demand toward personalized medicine are key factors to drive the growth of the market.

Effective product approvals is expected to drive the global breast cancer drugs market growth

Some of the novel product launches are specifically aimed at breast cancer treatments that is previously untreatable are expected to boost the market growth.

For instance, Sacituzumab govitecan (Trodelvy) by Immunomedics is a trophoblast cell surface antigen 2 (TROP2)-targeted antibody-drug conjugate (ADC) approved by FDA in 2022 for third-line and later-line metastatic triple-negative disease.

The PD1 inhibitor pembrolizumab (Keytruda) by Merck & Co in combination with chemotherapy was approved by the FDA in November 2022 to treat patients with locally recurrent unresectable or metastatic triple-negative breast cancer express PDL1.

Therefore, these factors are projected to positively impact the market growth in the forecast period.

The increasing prevalence of breast cancer cases is expected to drive the global Breast cancer drugs market growth

The incidence of breast cancers is proliferating. According to the World Health Organization (WHO) scenario, breast cancer is the second most cancer occurring among women. It affects nearly 2.1 million women each year. The American Cancer Society's estimates for breast cancer in the United States for 2021 are that about 281,550 new cases of invasive breast cancer will be diagnosed in women. According to Breast Cancer Care, WA Incorporated in 2019; an estimated 19,371 Australian women were diagnosed with the breast cancer or approximately 53 each day, which accounts for roughly 14% of all new breast cancer cases are diagnosed; furthermore, according to Cancer Research UK, breast cancer is the most common cancer in United Kingdom, accounting for nearly 15% of all the new cancer cases. Furthermore, aging is considered as one of the greatest risk factors. According to Cancer Treatment Centers of America, women above 60 years of age are more likely to be diagnosed and only about 10% to 15% of cases occur in women younger than 45 years of age.

Adverse effects of therapeutics are likely to hamper the market growth

Adverse reactions arising from breast cancer therapeutics, such as targeted therapies, may limit the market growth in the near future. For instance, according to the American Cancer Society (ACS), targeted therapies have several side effects, namely, skin problems, gastrointestinal problems such as diarrhea, and high blood pressure. In cases of severe adverse reactions, the patient may not be able to use that particular drug and may have to move toward other types of therapeutics. For instance, severe side effects of targeted therapy include rashes in several parts of the body and also the occurrence of blisters. Similarly, immunotherapy has side effects such as, fatigue, nausea. These adverse effects are likely to impede the market growth.

COVID-19 Impact Analysis

The COVID-19 pandemic has negatively impacted healthcare systems globally and also on the market growth. According to the Centers for Disease Control and Prevention (CDC) and many medical professional organizations recommended that cancer screening and other health prevention services, along with elective surgeries, be postponed unless the risks outweighed the benefits and secure the hospital infrastructure for the treatment of COVID-19 patients. Thus, the COVID-19 pandemic has impacted the Ongoing clinical trials too. However, the situation is expected to improve gradually.

Segment Analysis

The targeted therapy segment is expected to hold largest share in this market segment

Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific cancer cells. Targeted therapies usually cause less harm to normal cells than chemotherapy or radiation therapy. Trastuzumab is also known for its brand name Herceptin, Herzuma, and Ontruzant. It's a monoclonal antibody. The greater adoption of this therapy is due to many novel product launches and the overwhelming number of drugs under this segment. For instance, Trastuzumab duocarmazine drug by Byondis, which targets HER2 is under Phase III trials, is expected to fuel the market growth.

The HER 2+ type segment is expected to hold largest share in this market segment

HER2+ type is identified as the most lucrative segment of the breast cancer drugs market. The growing incidence of HER2-positive breast cancer is the major factor attributed to the growth of this segment. According to an article published by F. Hoffman La Roche Ltd in 2017, it was estimated that approximately one in five women diagnosed with breast tumors would have HER2-positive cancer and approximately 20% of breast cancers are HER2-positive. Moreover, rapidly growing demand from emerging markets such as the Asia Pacific and Latin America is expected to drive growth during the forecast period further.

The hospitals segment is expected to hold largest share in this market segment

The hospitals held the largest share in the global testicular cancer market. This is mainly owing to increasing number of patients suffering from breast cancer cases which are treated in hospitals equipped with advanced infrastructure and adequate facilities. For instance, In 2022, there were 2.3 million women diagnosed with breast cancer and 685 000 deaths globally. As of the end of 2022, there were 7.8 million women alive who were diagnosed with breast cancer in the past 5 years, making it the world’s most prevalent cancer. Moreover, growing number of hospitals along with adequate reimbursement policies is also contributing to the growth of this segment. Also, the surgery can only be done under supervision of medical practitioners at these locations.

Geographical Analysis

North America region holds the largest market share of global breast cancer drugs market

North America served the largest share of the market due to the increasing prevalence of breast cancer cases. According to International Agency for Research on Cancer (IARC) published by the World Health Organization (WHO) in 2018, breast cancer ranks as the fifth leading cause of death in women, accounting for 627,000 deaths every year. Moreover, as per the American Cancer Society estimates, in the U.S., 266,120 new cases are expected to be diagnosed in women by 2018. Increasing awareness and presence of established R&D infrastructure are among the key factors contributing to growth of the market in North America. Moreover, presence of key players such as Pfizer, Inc.; Merck & Co., Inc.; Celgene Corporation; and AbbVie, Inc. in the region is expected to drive the growth. Rising awareness about the benefits of early detection of cancer has driven the U.S based companies to make considerable investments in the development of targeted therapy drugs. New product developments, acquisitions, collaborations, and regional expansions are some of the key strategic initiatives major players undertake to maintain stability in the market. For instance, in March 2017, Kisqali received the Food and Drug Administration (FDA) approved HR+/HER2 as the first-line treatment for metastatic breast cancer in combination with an aromatase inhibitor. Kisqali is the only CDK 4/6 inhibitor approved to treat advanced stages of this disease in the U.S.

Competitive Landscape

The global breast cancer drugs market is highly competitive with presence of global companies.  Some of the key players which are contributing to the growth of the market include Novartis AG, F. Hoffmann-La Roche Ltd., AbbVie, Inc., Eli Lilly and Company, AstraZeneca, Celgene Corporation, Merck & Co., Inc., Biocon Genzyme Corporation, MacroGenics, Inc., Janssen Global Services LLC, Onyx Pharmaceuticals Inc., Celldex Therapeutics, and BioNumerik Pharmaceuticals, Inc. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally. For instance,

Breast Cancer Drugs Market Key Companies to Watch

F. Hoffmann-La Roche Ltd

Company Overview: Roche was founded in 1896 in Basel, Switzerland. It creates innovative medicines and diagnostic tests that help millions of patients globally. Roche was one of the first companies to bring targeted treatments to patients. With combined strength in pharmaceuticals and diagnostics, they are better equipped than any other company to drive personalized healthcare further. Two-thirds of their research and development projects are being developed with companion diagnostics. Genentech become a member of the Roche Group in March of 2009. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

Product Portfolio: The company portfolio includes Oncology, Neurology, Endocrinology, Infectious diseases, and others.

Key Developments: GDC-0077, by Roche/Genentech which acts on PI3K, is under Phase II/III is expected to complete by 2022.

Trending Topics

Oncology Nutrition Market

Skin Cancer Market

Leukemia Market

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report



Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!

linkedinpinterest